SG11202004187UA - Lyophilized formulation of a monoclonal antibody against transthyretin - Google Patents
Lyophilized formulation of a monoclonal antibody against transthyretinInfo
- Publication number
- SG11202004187UA SG11202004187UA SG11202004187UA SG11202004187UA SG11202004187UA SG 11202004187U A SG11202004187U A SG 11202004187UA SG 11202004187U A SG11202004187U A SG 11202004187UA SG 11202004187U A SG11202004187U A SG 11202004187UA SG 11202004187U A SG11202004187U A SG 11202004187UA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibody
- antibody against
- lyophilized formulation
- transthyretin
- against transthyretin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592294P | 2017-11-29 | 2017-11-29 | |
PCT/US2018/062902 WO2019108689A1 (en) | 2017-11-29 | 2018-11-28 | Lyophilized formulation of a monoclonal antibody against transthyretin |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202004187UA true SG11202004187UA (en) | 2020-06-29 |
Family
ID=66665773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004187UA SG11202004187UA (en) | 2017-11-29 | 2018-11-28 | Lyophilized formulation of a monoclonal antibody against transthyretin |
Country Status (18)
Country | Link |
---|---|
US (1) | US11873332B2 (en) |
EP (1) | EP3717512A4 (en) |
JP (1) | JP7337057B2 (en) |
KR (1) | KR20200090164A (en) |
CN (1) | CN111433223B (en) |
AU (1) | AU2018375356A1 (en) |
BR (1) | BR112020010483A2 (en) |
CA (1) | CA3083356A1 (en) |
CL (1) | CL2020001391A1 (en) |
CU (1) | CU20200042A7 (en) |
EA (1) | EA202091130A1 (en) |
IL (1) | IL274958A (en) |
JO (1) | JOP20200132A1 (en) |
MA (1) | MA51223A (en) |
MX (1) | MX2020005433A (en) |
PE (1) | PE20211453A1 (en) |
SG (1) | SG11202004187UA (en) |
WO (1) | WO2019108689A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
MX2020003041A (en) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anti-transthyretin antibodies. |
MX2020005433A (en) | 2017-11-29 | 2020-08-27 | Prothena Biosciences Ltd | Lyophilized formulation of a monoclonal antibody against transthyretin. |
JP7266108B2 (en) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | therapeutic antibody formulation |
JP2023525790A (en) | 2020-05-12 | 2023-06-19 | ニューリミューン エイジー | Combination therapy for TTR amyloidosis |
JP2023548005A (en) * | 2020-10-28 | 2023-11-15 | ノヴォ ノルディスク アー/エス | Anti-transthyretin antibody and its use |
CN113845593B (en) * | 2021-10-27 | 2023-03-10 | 福州迈新生物技术开发有限公司 | anti-alpha-SMA protein monoclonal antibody, cell line and application thereof |
CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
WO2024105092A1 (en) | 2022-11-15 | 2024-05-23 | Neurimmune Ag | Pharmaceutical compositions for treating or preventing transthyretin-mediated amyloidosis |
WO2024105062A1 (en) | 2022-11-15 | 2024-05-23 | Neurimmune Ag | Methods for treating or preventing transthyretin-mediated amyloidosis |
WO2024123791A1 (en) * | 2022-12-05 | 2024-06-13 | Kodiak Sciences Inc. | Formulations for dual vegf/il-6 inhibitors |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
EP1353944A2 (en) | 2000-04-05 | 2003-10-22 | The University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
WO2010012004A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
WO2010011999A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
CA2498407A1 (en) | 2002-09-12 | 2004-03-25 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
EP1660533A4 (en) | 2003-09-12 | 2009-10-21 | Univ California | Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
US8236933B2 (en) | 2005-04-13 | 2012-08-07 | Garvan Institute Of Medical Research | Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor |
JP5823663B2 (en) | 2006-03-03 | 2015-11-25 | プロミス ニューロサイエンシズ インコーポレイテッド | Methods and compositions for treating and detecting misfolded SOD1-mediated diseases |
WO2008005455A2 (en) | 2006-07-03 | 2008-01-10 | The Johns Hopkins University | Peptide antibody depletion and its application to mass spectrometry sample preparation |
EP2078189B1 (en) | 2006-10-20 | 2012-10-10 | Clondiag GmbH | Assay devices and methods for the detection of analytes |
WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
DK2342220T3 (en) | 2008-10-06 | 2021-08-09 | Univ British Columbia | METHODS AND SYSTEMS FOR PREDICTING MISFOLD PROTEIN PITOPES |
JP2010195710A (en) | 2009-02-25 | 2010-09-09 | Kumamoto Univ | Amyloid fibril formation inhibitor and use thereof |
WO2010099612A1 (en) | 2009-03-02 | 2010-09-10 | The University Of British Columbia | Antibodies and epitopes specific to misfolded prion protein |
TWI667346B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
FI20115165A0 (en) | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Therapeutic and diagnostic methods |
WO2012115241A1 (en) | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | Fcγriib-specific fc antibody |
EP3825325A3 (en) | 2011-03-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
TW201326209A (en) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
DK2857419T3 (en) | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule for the elimination of aggregated antigens |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
US9534048B2 (en) | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
US9790269B2 (en) | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
WO2014142334A1 (en) | 2013-03-12 | 2014-09-18 | 国立大学法人名古屋大学 | Method for increasing photosynthesis and yield of plants |
WO2015010118A2 (en) | 2013-07-19 | 2015-01-22 | The University Of Texas | Transthyretin amyloid-selective and polyreactive catabodies |
KR102496162B1 (en) | 2013-12-20 | 2023-02-09 | 뉴리뮨 홀딩 아게 | Antibody-based therapy of transthyretin(ttr) amyloidosis and human-derived antibodies therefor |
KR102240417B1 (en) | 2014-01-29 | 2021-04-13 | 케이엠 바이올로직스 가부시키가이샤 | Anti-transthyretin human antibody |
JP6818268B2 (en) | 2014-01-29 | 2021-01-20 | Kmバイオロジクス株式会社 | Anti-transthyretin humanized antibody |
SI3185957T1 (en) | 2014-08-29 | 2022-11-30 | Alnylam Pharmaceuticals, Inc. | Patisiran for use in treating transthyretin mediated amyloidosis |
TWI705827B (en) * | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | Methods for treating ocular diseases |
TWI769570B (en) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI718122B (en) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI718121B (en) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
JP7076711B2 (en) | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
JP7016470B2 (en) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
JP7017013B2 (en) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
CN107389956B (en) * | 2017-08-31 | 2019-05-07 | 北京臻惠康生物科技有限公司 | New application and its kit of the transthyretin as TBI patient injury's Severity |
MX2020003041A (en) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anti-transthyretin antibodies. |
JP7292569B2 (en) | 2017-10-06 | 2023-06-19 | ノボ ノルディスク エー/エス | Methods for detecting transthyretin |
MX2020005433A (en) | 2017-11-29 | 2020-08-27 | Prothena Biosciences Ltd | Lyophilized formulation of a monoclonal antibody against transthyretin. |
WO2021168156A1 (en) | 2020-02-20 | 2021-08-26 | Prothena Biosciences Limited | Monitoring transthyretin amyloidosis |
-
2018
- 2018-11-28 MX MX2020005433A patent/MX2020005433A/en unknown
- 2018-11-28 CN CN201880076019.0A patent/CN111433223B/en active Active
- 2018-11-28 JP JP2020528890A patent/JP7337057B2/en active Active
- 2018-11-28 PE PE2020000653A patent/PE20211453A1/en unknown
- 2018-11-28 WO PCT/US2018/062902 patent/WO2019108689A1/en active Application Filing
- 2018-11-28 MA MA051223A patent/MA51223A/en unknown
- 2018-11-28 EP EP18882542.6A patent/EP3717512A4/en active Pending
- 2018-11-28 AU AU2018375356A patent/AU2018375356A1/en not_active Abandoned
- 2018-11-28 EA EA202091130A patent/EA202091130A1/en unknown
- 2018-11-28 BR BR112020010483-3A patent/BR112020010483A2/en not_active IP Right Cessation
- 2018-11-28 KR KR1020207015129A patent/KR20200090164A/en not_active Application Discontinuation
- 2018-11-28 SG SG11202004187UA patent/SG11202004187UA/en unknown
- 2018-11-28 US US16/767,994 patent/US11873332B2/en active Active
- 2018-11-28 CA CA3083356A patent/CA3083356A1/en active Pending
- 2018-11-28 JO JOP/2020/0132A patent/JOP20200132A1/en unknown
- 2018-11-28 CU CU2020000042A patent/CU20200042A7/en unknown
-
2020
- 2020-05-26 IL IL274958A patent/IL274958A/en unknown
- 2020-05-27 CL CL2020001391A patent/CL2020001391A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200090164A (en) | 2020-07-28 |
PE20211453A1 (en) | 2021-08-05 |
CN111433223B (en) | 2024-08-27 |
CA3083356A1 (en) | 2019-06-06 |
CU20200042A7 (en) | 2021-03-11 |
EA202091130A1 (en) | 2020-08-28 |
MX2020005433A (en) | 2020-08-27 |
WO2019108689A1 (en) | 2019-06-06 |
MA51223A (en) | 2020-10-07 |
IL274958A (en) | 2020-07-30 |
BR112020010483A2 (en) | 2020-10-20 |
JP7337057B2 (en) | 2023-09-01 |
AU2018375356A1 (en) | 2020-05-14 |
JP2021504372A (en) | 2021-02-15 |
CL2020001391A1 (en) | 2020-11-13 |
EP3717512A1 (en) | 2020-10-07 |
US11873332B2 (en) | 2024-01-16 |
US20200362023A1 (en) | 2020-11-19 |
CN111433223A (en) | 2020-07-17 |
JOP20200132A1 (en) | 2022-10-30 |
EP3717512A4 (en) | 2021-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274958A (en) | Lyophilized formulation of a monoclonal antibody against transthyretin | |
IL279321A (en) | Anti-sirpα antibody | |
SG11202001368SA (en) | Antigen-binding proteins tatrgeting shared antigens | |
IL273411A (en) | Anti-pd-l1 antibody and uses thereof | |
ZA202006797B (en) | Anti-rsv monoclonal antibody formulation | |
EP3587453A4 (en) | Anti-pd-l1 antibody and application thereof | |
EP3441086A4 (en) | Anti-pd-1 monoclonal antibody | |
EP3532489A4 (en) | Neutralizing anti-tl1a monoclonal antibodies | |
IL270698A (en) | Canine antibody libraries | |
EP3480216A4 (en) | Anti-pcsk9 monoclonal antibody | |
ZA202101177B (en) | Anti-btla antibody | |
EP3103811A4 (en) | Anti-tissue factor monoclonal antibody | |
EP3590964A4 (en) | Improved anti-vegfr-2 monoclonal antibody | |
HK1246805A1 (en) | Broad-spectrum monoclonal anti-flu b antibody and uses thereof | |
EP3567053A4 (en) | Anti-claudin-2 monoclonal antibody | |
IL281717A (en) | Antibody formulation | |
IL282813A (en) | Antibody formulation | |
ZA202006263B (en) | Antibody formulation | |
GB201811368D0 (en) | Antibody | |
EP3432925A4 (en) | Administration of an anti-lgr5 monoclonal antibody | |
GB201817172D0 (en) | Antibody | |
EP3498838A4 (en) | Anti-pd-l1 antibody | |
EP3365367A4 (en) | Anti-bed bug monoclonal antibodies and methods of making and uses thereof | |
EP3404042A4 (en) | Monoclonal antibody fnab8 and application thereof | |
HUE062818T2 (en) | Ce-western applications for antibody development |